Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
09/2005
09/22/2005US20050208128 Immediate release tablet
09/22/2005US20050208070 From Ganoderma lucidum, Salvia miltiorrhiza, and Scutellaria barbata
09/22/2005US20050208048 HLA-DR specific antibodies, compositions and methods
09/22/2005US20050208020 Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
09/22/2005US20050207988 Polysaccharides for pulmonary delivery of active agents
09/21/2005EP1576010A2 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
09/21/2005EP1575673A2 Use of a trpm8-activating substance for the treatment of tumours
09/21/2005EP1575621A2 Contrast media formulations having improved biological tolerance
09/21/2005EP1575602A2 Methods for treating cancer using porimin as a target
09/21/2005EP1575576A2 Organic compounds
09/21/2005EP1575574A2 Methods for treating and preventing apoptosis-related diseases using rna interfering agents
09/21/2005EP1575565A1 Modified-release tablet of bupropion hydrochloride
09/21/2005EP1575553A2 In vivo production of cyclic peptides for inhibiting protein-protein interaction
09/21/2005EP1575549A2 Identification of anti-hiv compounds inhibiting virus assembly and binding of nucleocapsid protein to nucleic acid
09/21/2005EP1575548A2 Compositions and methods for promoting neuronal outgrowth
09/21/2005EP1575531A2 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-&bgr;
09/21/2005EP1575526A2 Dna vaccines encoding heat shock proteins
09/21/2005EP1575520A2 A process for preparation of an agglutination reagent for rapid detection of typhoid
09/21/2005EP1575518A2 Compositions, organisms and methodologies employing a novel human kinase
09/21/2005EP1575511A2 A new target for angiogenesis and anti-angiogenesis therapy
09/21/2005EP1575510A2 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
09/21/2005EP1575503A2 Compositions and methods for treating and preventing infection
09/21/2005EP1575498A2 Antisense modulation of microsomal prostaglandin e2 synthase expression
09/21/2005EP1575497A2 Novel composition and methods for the treatment of psoriasis
09/21/2005EP1575487A2 Microcrystalline cewllulose compositions
09/21/2005EP1575485A2 Methods for lightening skin and hair
09/21/2005EP1200115B1 Multi-dose erythropoietin formulations
09/21/2005EP1198222B1 Skin care composition
09/21/2005EP1198221B1 Skin care composition
09/21/2005EP1192256B1 Global regulators of bacterial pathogenic genes; bacterial autoinducer inactivation protein, as targets for engineering disease resistance
09/21/2005CN1671420A Pegylated factor VII glycoforms
09/21/2005CN1671412A Immunostimulatory compositions and methods of stimulating an immune response
09/21/2005CN1669559A Medicine for treating rhinitis
09/21/2005CN1219764C W-carboxyaryl substituted diphenyl ureas as RAF kinase inhibitors
09/21/2005CN1219514C Oral medicine preparation with high absorbency
09/20/2005US6946579 3-carbocycle carbonyl-3-phenylpropionaldehyde intermediates and preparation by alkylating a carbocycle benzyl ketone with an allyl halide and oxidizing the product
09/20/2005US6946490 Medicine comprises Echinacea phytochemicals and benzalkonium chloride in a sterile water solution; for therapy
09/20/2005US6946299 Meauring instruments comprising containers, electrodes and switches, used for analyzing sugar concentration in blood
09/20/2005US6946137 Methods for the controlled delivery of pharmacologically active compounds
09/15/2005WO2005055940A3 Novel m3 muscarinic acetylcholine receptor antagonists
09/15/2005WO2005055935A3 Cationic substituted benzofurans as antimicrobial agents
09/15/2005WO2005055925A8 14-3-3 zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types
09/15/2005WO2005053612A3 Micellar systems useful for delivery of lipophilic or hydrophobic compounds
09/15/2005WO2005051300A3 Bicyclic inhibitors of mek and methods of use thereof
09/15/2005WO2005046578A3 Isoquinolinone potassium channel inhibitors
09/15/2005WO2005044199A3 Combination of proton pump inhibitor and sleep aid
09/15/2005WO2005044185A3 Electromagnetic field regulating compositions
09/15/2005WO2005039496A3 Inhibitors of cathepsin s
09/15/2005WO2005039484A3 Indolocarbazole anticancer agents and methods of using same
09/15/2005WO2005034841A3 Anthrax vaccine
09/15/2005WO2005032494A3 Lpa receptor agonists and antagonists and methods of use
09/15/2005WO2005032479A3 Compositions and methods for selective inhibition of nicotine acetylcholine receptors
09/15/2005WO2005030143A3 Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
09/15/2005WO2005025504A3 Modulators of calcitonin and amylin activity
09/15/2005WO2005023181B1 Polymeric systems for controlled drug therapy
09/15/2005WO2005020907A9 Ocular drug delivery device
09/15/2005WO2005020900A3 Delivery of a therapeutic agent in a formulation for reduced toxicity
09/15/2005WO2005018547A3 Mitotic kinesin inhibitors
09/15/2005WO2005018536A3 Agonist antibodies that specifically bind the glucagon like peptide-1 receptor
09/15/2005WO2005016256A3 Hemostatic compositions containing sterile thrombin
09/15/2005WO2005016232A3 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
09/15/2005WO2005009389A3 Anaplastic lymphoma kinase modulators and methods of use
09/15/2005WO2005000210A3 Synthesis of high molecular weight iron-saccharidic complexes
09/15/2005WO2005000204A3 Pancreatic cancer treatment
09/15/2005WO2004110372A3 Room temperature storage of organs
09/15/2005WO2004103260A3 Ternary and quaternary eutectic mixtures.
09/15/2005WO2004093810A3 Methods and compositions for treating disorders
09/15/2005WO2004093793A3 Delivery vehicle for silver ions
09/15/2005WO2004091514A3 Cgrp receptor antagonists
09/15/2005WO2004089284A3 Targets for tumor growth inhibition
09/15/2005WO2004073644A3 Water-soluble silk proteins in compositions for skin care, hair care or hair coloring
09/15/2005WO2004069168A3 Novel antiherpes drug combinations
09/15/2005WO2004066922A3 A method of treating breast cancer with androgen receptor antagonists
09/15/2005WO2004064770A3 Use of smad3 inhibitor in the treatment of fibrosis dependent on epithelial to mesenchymal transition as in the eye and kidney
09/15/2005WO2004060313A3 Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses
09/15/2005WO2004056307A3 Disease treatment via antimicrobial peptide inhibitors
09/15/2005US20050203142 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
09/15/2005US20050203084 Protease inhibitors
09/15/2005US20050203063 Proteasome pathway inhibitors and related methods
09/15/2005US20050203000 Use of benzyl alcohol, and other phenolic preservatives to reduce pain during intradermal injection
09/15/2005US20050202529 Humanised antibodies
09/15/2005US20050202463 Modulators of dimethylarginine dimethylaminohydrolase and methods of use thereof
09/15/2005US20050202105 Mixing with water to solubilize thermal aqueous extractable phytocompounds
09/15/2005US20050202093 Prolonged suppression of electrical activity in excitable tissues
09/15/2005US20050202084 Pharmaceutical compositions
09/15/2005US20050202066 Citric acid and a quaternary ammonium compound, an oxidizing agent of a halogen compound
09/15/2005US20050202033 Heat shock protein-based vaccines and immunotherapies
09/15/2005US20050202022 Polynucleotides encoding humanized antibodies against human 4-1BB
09/15/2005US20050202010 Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
09/15/2005US20050201978 Comprising lectin coupled to an immunogeniciety modifier, pokeweed mitogen and with a coating of polyoxyethylene glycol; inhibit isoclass immunoglobulin switching; side effet reduction; antitumor, -carcinogenisis and -metastasis agents; bactericides; fungicide;antiprotazoa agents; side effect reduction
09/14/2005EP1574214A1 Pharmaceutical composition comprising fenofibrate and process for its preparation
09/14/2005EP1573048A2 Breast specific protein expressed in cancer and methods of use thereof
09/14/2005EP1573039A2 Compositions and methods for diagnosing and treating mood disorders
09/14/2005EP1573004A2 Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
09/14/2005EP1572744A2 Immunoglobulin variants and uses thereof
09/14/2005EP1572678A2 Substituted n-phenyl sulfonamide bradykinin antagonists
09/14/2005EP1572220A1 Antiviral, anti-infectious and cicatrising properties of extracts of dichrostachys glomerata
09/14/2005EP1572218A2 Ester combination local anesthetic
09/14/2005EP1572170A2 Immunotoxin as a therapeutic agent and uses thereof
09/14/2005EP1572154A2 Medical devices employing novel polymers
1 ... 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 ... 295